Compounds and pharmaceutical compositions for treating diseases associated with reperfusion injury

By using the compounds represented by Formula 1, the problem of poor effectiveness of existing drugs in the treatment of cerebral ischemia-reperfusion injury was solved, and the effect of significantly reducing the infarction volume and improving neurological function was achieved.

CN120168457APending Publication Date: 2025-06-20SUZHOU YIPU PHARMACEUTICAL TECHNOLOGY CO LTD
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202311753542.1
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2023-12-19
Publication Date
2025-06-20

AI Technical Summary

Technical Problem

Existing drugs are not effective in treating cerebral ischemia-reperfusion injury and cannot take effect in time, resulting in irreversible disability of patients.

Method used

A compound represented by Formula 1 or a pharmaceutically acceptable salt or stereoisomer thereof is provided for the preparation of a drug for the treatment of diseases associated with reperfusion injury. The compound can be used independently or in combination with pharmaceutically acceptable excipients.

Benefits of technology

By using this compound, the severity of cerebral ischemia-reperfusion injury can be significantly reduced, infarction volume can be reduced, neurological scores can be improved, and more effective therapeutic effects can be provided.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN120168457A_ABST
    Figure CN120168457A_ABST
Patent Text Reader

Abstract

The invention relates to a compound and a pharmaceutical composition for treating diseases related to reperfusion injury, in particular to a compound represented by a formula 1 or pharmaceutically acceptable salts or stereoisomers thereof, and a pharmaceutical composition comprising the compound represented by the formula 1 and pharmaceutically acceptable auxiliary materials, and their use in the preparation of medicaments for the treatment of reperfusion injury related diseases. # imgabs0 #
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present disclosure relates to the field of medicine, and more specifically, the present disclosure relates to a compound represented by Formula 1 or a pharmaceutically acceptable salt or stereoisomer thereof, a pharmaceutical composition comprising the compound represented by Formula 1 and one or more pharmaceutically acceptable excipients, and the use of the compound or its pharmaceutical composition in the preparation of a medicament for treating a disease associated with reperfusion injury. Background Art

[0002] "Brain injury" generally refers to brain injuries caused by various reasons, including not only brain injuries caused by simple brain trauma, but also brain injuries caused by various diseases. Such as hemorrhagic vascular diseases, ischemic vascular diseases, tumors, genetic metabolic diseases, etc. of the brain may cause brain injury.

[0003] "Reperfusion injury", also known as "ischemia-reperfusion injury", refers to the situation where the degree of tissue injury rapidly increases after the tissue cells that have suffered ischemia for a certain period of time resume blood flow (reperfusion). The clinical diseases caused by this are called reperfusion syndromes. After reperfusion, a large amount of Ca influx occurs and a large amount of oxygen free radicals are generated, which is the main pathogenesis of extensive tissue cell injury. Clinically, the occurrence and development of various diseases such as delayed neuronal necrosis, irreversible shock, myocardial infarction, acute organ failure, and organ transplantation rejection are related to ischemia and reperfusion.

[0004] Cerebral ischemia-reperfusion injury is a common disease clinically. The characteristics of this disease are that there are many causes and there are also many drugs used clinically, but the therapeutic effects exerted by most drugs are relatively weak. The incidence, disability rate, and mortality rate of cerebral ischemia-reperfusion injury in our country are very high. Cerebral ischemia-reperfusion injury is an extremely complex pathophysiological process. At present, the drugs commonly used clinically to treat cerebral ischemia-reperfusion injury often have poor effects and cannot take effect in time. Even if they take effect, the effects are not good, causing irreversible disabilities to patients and leaving lifelong regrets.

[0005] Therefore, there is an urgent need for a drug that can very effectively treat diseases associated with reperfusion injury. Summary of the Invention

[0006] In one aspect of the present disclosure, there is provided the use of a compound represented by Formula 1 or a pharmaceutically acceptable salt or stereoisomer thereof in the preparation of a medicament for treating a disease associated with reperfusion injury,

[0007]

[0008] wherein: X can be carbon or nitrogen;

[0009] R1 and R2 are the same as or different from each other, and each independently is unsubstituted or substituted by at least one R 10a substituted hydroxy group, unsubstituted or substituted by at least one R 10a substituted sulfo group, unsubstituted or substituted by at least one R 10a substituted C1-C 10 alkoxy group, unsubstituted or substituted by at least one R 10a substituted C1-C 10 alkyl acyloxy group, unsubstituted or substituted by at least one R 10a substituted C1-C 10 alkylsulfonyl group, unsubstituted or substituted by at least one R 10a substituted C3-C 12 cycloalkyloxy group, unsubstituted or substituted by at least one R 10a substituted C3-C 12 cycloalkyl acyloxy group, unsubstituted or substituted by at least one R 10a substituted C3-C 12 cycloalkylsulfonyl group, unsubstituted or substituted by at least one R 10a substituted C4-C 13 cycloalkylalkoxy group, unsubstituted or substituted by at least one R 10a substituted C6-C 20 aryloxy group, unsubstituted or substituted by at least one R 10a substituted C6-C 20 aryl acyloxy group, unsubstituted or substituted by at least one R 10a substituted C6-C 20 arylsulfonyl group, unsubstituted or substituted by at least one R 10a substituted C7-C 21 arylalkoxy group, unsubstituted or substituted by at least one R 10a substituted C2-C 12 heterocyclyloxy group, unsubstituted or substituted by at least one R 10a substituted C2-C 12 heterocyclic acyloxy group, unsubstituted or substituted by at least one R 10a substituted C2-C 12 heterocyclic sulfonyl group, unsubstituted or substituted by at least one R 10a substituted C3-C 13 heterocyclic alkoxy group, unsubstituted or substituted by at least one R 10a substituted C2-C 10 carbonate alkoxy group, or unsubstituted or substituted by at least one R 10a substituted glutamine group,

[0010] R1 and R2 are optionally bonded to each other to form a heterocyclic group containing at least two oxygen atoms as ring-forming atoms.

[0011] In an embodiment, R1 and R2 are each independently a hydroxyl group; a sulfo group; a C1-C 10 alkoxy group; a glutamine group; a C2-C optionally substituted with a C1-C6 alkyl 12 heterocyclylcarbonyloxy group; a C7-C optionally substituted with a C2-C optionally substituted by a C1-C6 alkyl 12 heterocyclic group; an arylalkoxy group; a C2-C 21 carbonate alkoxy group. 10

[0012] In another embodiment, R1 and R2 are bonded to each other to form an unsubstituted or at least one R- 10a substituted C2-C 12 dioxolanyl group, an unsubstituted or at least one R- 10a substituted C2-C 12 dioxaborolanyl group, an unsubstituted or at least one R- 10a substituted C2-C 12 dioxazolidinyl group, or an unsubstituted or at least one R- 10a substituted C2-C 12 dioxathiolanyl group. In yet another embodiment, R1 and R2 are bonded to each other to form an unsubstituted or at least one R- 10a substituted dioxolane group, an unsubstituted or at least one R- 10a substituted dioxane group, an unsubstituted or at least one R- 10a substituted dioxaborolane group, or an unsubstituted or at least one R- 10a substituted dioxaborinane group. In still another embodiment, R1 and R2 are bonded to each other to form an optionally oxo, formyloxy, acetyloxy, C1-C6 alkyl, C1-C6 alkoxy, C6-C optionally substituted by a C1-C6 alkoxy 12 aryl group, a C7-C optionally substituted by a C1-C6 alkoxy 13 aralkyl group, or a dioxolane group, dioxane group or dioxaborolane group substituted by a C2-C optionally substituted by a hydroxyl, formyloxy, acetyloxy, C1-C6 alkyl or C1-C6 alkoxy 12 heterocyclic group.

[0013] In a specific embodiment, R1 and R2 are each independently:

[0014] ​

[0015] or

[0016] R1 and R2 are bonded to each other to form:

[0017]

[0018] wherein, * and *' each represent a binding site to an adjacent atom on the benzene ring

[0019] In the present disclosure, R 10a is selected from deuterium; halogen; oxo; acylamino; formyloxy; acetoxy; C1-C6 alkyl group; C1-C6 alkoxy group; C6-C 12 aryl group which is unsubstituted or substituted by hydroxy, formyloxy, acetoxy, C1-C6 alkyl or C1-C6 alkoxy; C7-C 13 aralkyl group which is unsubstituted or substituted by hydroxy, formyloxy, acetoxy, C1-C6 alkyl or C1-C6 alkoxy; C2-C 12 heterocyclic group.

[0020] In an embodiment of the present disclosure, the compound represented by Formula 1 may be selected from the following Compound 1 to Compound 18:

[0021]

[0022]

[0023] In another aspect of the present disclosure, there is provided a compound represented by Formula 1:

[0024]

[0025] or a pharmaceutically acceptable salt or stereoisomer thereof,

[0026] wherein, X, R1 and R2 may each independently be the same as defined above,

[0027] However, the compound represented by Formula 1 in this aspect is not 4-allylcatechol, that is,

[0028]

[0029] In yet another aspect of the present disclosure, there is provided a pharmaceutical composition, which comprises the compound represented by Formula 1 described above, and a pharmaceutically acceptable excipient.

[0030] In yet another aspect of the present disclosure, there is also provided the use of a pharmaceutical composition in the preparation of a medicament for treating a disease associated with reperfusion injury. BRIEF DESCRIPTION OF THE DRAWINGS

[0031] Figure 1 Shows the metabolic pathway of Compound 1 in SD rats, as well as the structure and content distribution of the corresponding metabolites.

[0032] Figure 2A Shows the change in the content of metabolite M4 of Compound 1 (administered by gavage) in SD rats; Figure 2B Shows the change in the content of metabolite M4 of Compound 1 (administered by intravenous injection) in SD rats; Figure 2C Shows the change in the content of metabolite M5 of Compound 1 (administered by gavage) in SD rats; Figure 2D Shows the change in the content of metabolite M5 of Compound 1 (administered by intravenous injection) in SD rats; Figure 2E Shows the change in the content of metabolite M7 of Compound 1 (administered by gavage) in SD rats; and Figure 2F Shows the change in the content of metabolite M7 of Compound 1 (administered by intravenous injection) in SD rats. DETAILED DESCRIPTION

[0033] The following detailed description will be better understood when read in conjunction with the accompanying drawings. To illustrate the invention, the drawings illustrate embodiments of the invention. However, the invention is not limited to the precise arrangements, examples, and means shown.

[0034] The terms used herein are for the purpose of describing particular embodiments and are not intended to be limiting. In addition, the terms "comprising" and / or "including" when used in this specification specify the presence of the stated features, integers, steps, operations, elements, components, and / or groups thereof, but do not preclude the presence or addition of one or more other features, integers, steps, operations, elements, components, and / or groups thereof.

[0035] Unless otherwise defined, all terms used herein (including technical and scientific terms) have the same meaning as commonly understood by one of ordinary skill in the art to which this disclosure pertains. Terms (such as those defined in common dictionaries) should be interpreted as having a meaning consistent with their meaning in the context of the relevant field and should not be interpreted in an idealized or overly formal sense unless expressly so defined herein.

[0036] Definition

[0037] As used herein, the term "substituted", when used with respect to a chemical substituent or moiety (e.g., a C1-C6 alkyl group), means that one or more hydrogen atoms of the substituent or moiety have been replaced by one or more non-hydrogen atoms or groups, provided that the valence requirements are met and the substitution results in a chemically stable compound.

[0038] As used herein, the term "about" or "approximately", when used in conjunction with a numerical variable, refers to the indicated value of the variable and all values within the experimental error of the indicated value or within ±15%, ±10%, or ±5% of the indicated value.

[0039] As used herein, the term "alkyl group" refers to straight-chain and branched-chain saturated hydrocarbon groups having a specified number of carbon atoms (e.g., C1-C6 alkyl refers to an alkyl group having from 1 to 6 (i.e., 1, 2, 3, 4, 5, or 6) carbon atoms, and C1-C 10 alkyl refers to an alkyl group having from 1 to 10 carbon atoms). Examples of alkyl groups include methyl, ethyl, n-propyl, isopropyl, n-butyl, sec-butyl, isobutyl, tert-butyl, pent-1-yl, pent-2-yl, pent-3-yl, 3-methylbut-1-yl, 3-methylbut-2-yl, 2,2,2-trimethyleth-1-yl, n-hexyl, and the like. "Alkylene group" refers to a divalent group having the same structure as the corresponding alkyl group.

[0040] As used herein, the term "alkenyl group" refers to a monovalent hydrocarbon group having at least one carbon-carbon double bond at the middle or end of an alkyl group (e.g., C2-C6 alkenyl refers to an alkenyl group having from 2 to 6 (i.e., 2, 3, 4, 5, or 6) carbon atoms). Examples of alkenyl groups can include vinyl group, propenyl group, butenyl group, and the like.

[0041] As used herein, the term "alkynyl group" refers to a monovalent hydrocarbon group having at least one carbon-carbon triple bond at the middle or end of an alkyl group (e.g., C2-C6 alkynyl refers to an alkynyl group having from 2 to 6 (i.e., 2, 3, 4, 5, or 6) carbon atoms). Examples of alkenyl groups can include ethynyl group, propynyl group, butynyl group, and the like.

[0042] As used herein, the term "cycloalkyl group" refers to a saturated cycloaliphatic group typically having a specified number of carbon atoms forming the ring (e.g., C 3-10 cycloalkyl refers to a cycloalkyl group having from 3 to 10 carbon atoms as ring-forming atoms). Examples of cycloalkyl groups include cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, and the like.

[0043] As used herein, the term "heterocycloalkyl group" refers to a cyclic group that further contains at least one heteroatom (where the number of heteroatoms can be 1 to 5 or 1 to 3, such as 1, 2, 3, 4, or 5) in addition to carbon atoms as ring-forming atoms (for example, C1-C6 heterocycloalkyl refers to a heterocycloalkyl group having at least one heteroatom and 1 to 6 carbon atoms as ring-forming atoms). Examples of heterocycloalkyl groups are oxetanyl, morpholinyl, etc.

[0044] As used herein, the terms "oxo" and "oxo group" are used interchangeably and refer to =O.

[0045] As used herein, the terms "halo" and "halogen" are used interchangeably and refer to fluorine, chlorine, bromine, and iodine.

[0046] As used herein, the term "hydroxy" refers to -OH, the term "sulfonyl" refers to -SO3H, the term "acyloxy" refers to -COO-, and the term "sulfonyl group" refers to -SO3-.

[0047] As used herein, the term "C6-C 20 aryl group" refers to a monovalent group having a carbocyclic aromatic system containing 6 to 20 carbon atoms (where the number of carbon atoms can be 6 to 15, 6 to 12, or 6 to 10). Examples of C6-C 20 aryl groups can be phenyl groups, naphthyl groups, indenyl groups, anthracenyl groups, etc.

[0048] As used herein, the term "C1-C 20 heteroaryl group" refers to a monovalent group of a heterocyclic aromatic system that further contains at least one heteroatom (where the number of heteroatoms can be 1 to 5 or 1 to 3, such as 1, 2, 3, 4, or 5) in addition to carbon atoms and 1 to 20 carbon atoms as ring-forming atoms. Examples of heteroaryl groups are pyridyl, benzimidazolyl, etc.

[0049] As used herein, the term "C3-C 12 carbocyclic group" refers to a monovalent group of a ring system containing 3 to 12 carbon atoms (where the number of carbon atoms can be 3 to 10 or 3 to 6) that contains only carbon atoms as ring-forming atoms. Carbocyclic groups can include cycloalkyl and aryl groups.

[0050] As used herein, the term "C1-C 20 heterocyclic group" refers to a monovalent group of a heterocyclic system that further contains at least one heteroatom (where the number of heteroatoms can be 1 to 5 or 1 to 3, such as 1, 2, 3, 4, or 5) in addition to carbon atoms and 1 to 20 carbon atoms (where the number of carbon atoms can be 1 to 15, 1 to 12, 1 to 10, or 1 to 6) as ring-forming atoms. Heterocyclic groups can include heterocycloalkyl and heteroaryl groups.

[0051] As used herein, the term "heteroatom" refers to any atom other than a carbon atom and a hydrogen atom. Examples of heteroatoms are O, S, N, P, Si, B, Ge, Se, or any combination thereof.

[0052] As used herein, the term "carbonate group" refers to R-O-COO-, where R can be an alkyl group, an aryl group, or a heterocyclic group. For example, "C1-C 10 carbonate group" means that the R moiety has 1 to 10 carbon atoms, excluding the carbon atoms contained in the carbonate, and "C2-C 10 carbonate group alkoxy" means that the total number of carbon atoms in the R moiety and the alkoxy moiety is 2 to 10.

[0053] As used herein, the term "glutamine group" refers to the residue after glutamine has lost a hydroxyl group.

[0054] Furthermore, when prefixes are named in sequence, this means that substituents are listed in the order first described. For example, arylalkoxy means an alkoxy group substituted with an aryl group, alkoxyacyloxy means an acyloxy group substituted with an alkoxy group, and so on.

[0055] As used herein, the term "pharmaceutically acceptable" refers to those compounds, materials, compositions, and / or dosage forms that are suitable for contact with the tissues of humans and animals within the scope of reasonable medical judgment, without excessive toxicity, irritation, allergic reaction, or other problems or complications, and that meet a reasonable benefit / risk ratio.

[0056] As used herein, the term "pharmaceutically acceptable salt" refers to a derivative of the disclosed compound, where the parent compound is modified by preparing its acid or base salt. Examples of pharmaceutically acceptable salts include, but are not limited to, salts derived from the following organic acids or inorganic acids: 1,2-ethanedisulfonic acid, 2-acetoxybenzoic acid, 2-hydroxyethanesulfonic acid, acetic acid, ascorbic acid, benzenesulfonic acid, benzoic acid, bicarbonic acid, carbonic acid, citric acid, ethylenediaminetetraacetic acid, ethanedisulfonic acid, ethanesulfonic acid, fumaric acid, glucoheptonic acid, gluconic acid, glutamic acid, glycolic acid, hexylresorcinolic acid, heptanoic acid, hydrobromic acid, hydrochloric acid, hydroiodic acid, hydroxymaleic acid, hydroxynaphthoic acid, hydroxyethanesulfonic acid, lactic acid, lactobionic acid, laurylsulfonic acid, maleic acid, malic acid, mandelic acid, methanesulfonic acid, naphthalenesulfonic acid, nitric acid, oxalic acid, pamoic acid, pantothenic acid, phenylacetic acid, phosphoric acid, salicylic acid, stearic acid, succinic acid, sulfamic acid, sulfanilic acid, sulfuric acid, tannic acid, tartaric acid, and toluenesulfonic acid.

[0057] As used herein, the term "patient" or "individual" is used to denote warm-blooded animals such as mammals, for example, cats, dogs, mice, guinea pigs, horses, cows, sheep, non-humans, and humans.

[0058] As used herein, the term "therapeutically effective amount" means that, when compared to an individual not receiving the active ingredient, that dose of the active ingredient can prevent, ameliorate, mitigate or cure a disease state, reduce one or more symptoms associated with the disease, or slow, arrest or reverse the progression of the disease. The therapeutically effective amount can be affected by a variety of factors, including but not limited to the properties of the active ingredient (e.g., activity, pharmacokinetics, pharmacodynamics, bioavailability, etc.), the condition of the individual to be treated (e.g., age, gender, disease type and stage, general health, response to a given dose, etc.), the dosage form of the drug, and the route of administration, etc.

[0059] Compound

[0060] In one aspect of the present disclosure, there is provided a compound represented by Formula 1 or a pharmaceutically acceptable salt or stereoisomer thereof,

[0061]

[0062] wherein: X can be carbon or nitrogen; R1 and R2 can each independently be an oxygen-containing group, or R1 and R2 can be bonded to each other to form a heterocyclic group containing at least two oxygen atoms as ring-forming atoms, wherein R1 and R2 can be the same or different from each other.

[0063] In an embodiment, R1 and R2 can each independently be an unsubstituted or at least one R 10a substituted hydroxy group, an unsubstituted or at least one R 10a substituted sulfo group, an unsubstituted or at least one R 10a substituted C1-C 10 alkoxy group, an unsubstituted or at least one R 10a substituted C1-C 10 alkyl acyloxy group, an unsubstituted or at least one R 10a substituted C1-C 10 alkylsulfonyl group, an unsubstituted or at least one R 10a substituted C3-C 12 cycloalkyloxy group, an unsubstituted or at least one R 10a substituted C3-C 12 cycloalkyl acyloxy group, an unsubstituted or at least one R 10a substituted C3-C 12 cycloalkylsulfonyl group, an unsubstituted or at least one R 10a substituted C4-C 13 cycloalkylalkoxy group, an unsubstituted or at least one R 10a substituted C6-C 20 aryloxy group, an unsubstituted or at least one R10a Substituted C6-C 20 arylacyloxy group, unsubstituted or substituted by at least one R 10a Substituted C6-C 20 arylsulfonyl group, unsubstituted or substituted by at least one R 10a Substituted C7-C 21 arylalkoxy group, unsubstituted or substituted by at least one R 10a Substituted C2-C 12 heterocyclyloxy group, unsubstituted or substituted by at least one R 10a Substituted C2-C 12 heterocyclylacyloxy group, unsubstituted or substituted by at least one R 10a Substituted C2-C 12 heterocyclylsulfonyl group, unsubstituted or substituted by at least one R 10a Substituted C3-C 13 heterocyclylalkoxy group, unsubstituted or substituted by at least one R 10a Substituted C1-C 10 carbonatealkoxy group, or unsubstituted or substituted by at least one R 10a substituted glutamine group.

[0064] In another embodiment, R1 and R2 can each independently be a hydroxyl group; a sulfo group; a C1-C 10 alkoxy group; a glutamine group; a C2-C 12 heterocyclylacyloxy group optionally substituted by C1-C6 alkyl; a C7-C 12 arylalkoxy group substituted by a heterocyclic group optionally substituted by C1-C6 alkyl; a C1-C 21 carbonatealkoxy group. 10

[0065] In one embodiment, R1 and R2 above can be bonded to each other to form a heterocyclic group containing at least two oxygen atoms as ring-forming atoms, for example, an unsubstituted or at least one R 10a Substituted C2-C 12 dioxolanyl group, unsubstituted or substituted by at least one R 10a Substituted C2-C 12 dioxaborolanyl group, unsubstituted or substituted by at least one R 10a Substituted C2-C 12 dioxazolidinyl group, or unsubstituted or substituted by at least one R 10a Substituted C2-C 12 dioxathiolanyl group.

[0066] In another embodiment, R1 and R2 may be bonded to each other to form an unsubstituted or substituted R 10a substituted dioxolane group, unsubstituted or replaced by at least one R 10a substituted dioxane group, unsubstituted or replaced by at least one R 10a substituted dioxaborolanyl groups, or unsubstituted or replaced by at least one R 10a More specifically, R1 and R2 may be bonded to each other to form a C6-C6 alkyl group optionally substituted by oxo, formyloxy, acetoxy, C1-C6 alkyl, C1-C6 alkoxy, C6-C6 alkoxy optionally substituted by C1-C6 alkoxy, or C6-C6 alkyl group optionally substituted by C1-C6 alkoxy. 12 Aryl group, C7-C6 alkoxy optionally substituted 13 an aralkyl group, or a C2-C6 alkyl group optionally substituted by a hydroxyl group, a formyloxy group, an acetoxy group, a C1-C6 alkyl group or a C1-C6 alkoxy group; 12 A dioxolane group, a dioxane group or a dioxaborolanyl group substituted with a heterocyclic group.

[0067] In this disclosure, R 10a can be independently selected from deuterium; halogen; oxo; acylamino; formyloxy; acetoxy; C1-C6 alkyl group; C1-C6 alkoxy group; C6-C6 alkyl group which is unsubstituted or substituted by hydroxyl, formyloxy, acetoxy, C1-C6 alkyl or C1-C6 alkoxy; 12 Aryl group; C7-C6 substituted unsubstituted or substituted by hydroxy, formyloxy, acetoxy, C1-C6 alkyl or C1-C6 alkoxy 13 Aralkyl group; C2-C6 alkyl group which is unsubstituted or substituted by hydroxyl, formyloxy, acetoxy, C1-C6 alkyl or C1-C6 alkoxy 12 Heterocyclic group.

[0068] In one embodiment, R1 and R2 can each independently be:

[0069]

[0070] or

[0071] R1 and R2 may be bonded to each other to form:

[0072]

[0073] Here, * and *' each represent a bonding site with an adjacent atom on the benzene ring.

[0074] In an embodiment, R1 and R2 can be the same as each other. For example, both R1 and R2 can be hydroxyl groups; alternatively, both R1 and R2 can be methoxy groups.

[0075] In an embodiment, R1 and R2 can also be different from each other. For example, R1 can be a hydroxyl group and R2 can be a methoxy group; alternatively, R1 can be a methoxy group and R2 can be a hydroxyl group.

[0076] In an embodiment of the present disclosure, the compound represented by Formula 1 can be selected from the following Compounds 1 to 18:

[0077]

[0078] Those skilled in the art should understand that the compound represented by Formula 1 according to the embodiment is not limited thereto.

[0079] The compounds provided herein include all diastereoisomeric, enantiomeric and epimeric forms and their appropriate mixtures. The compounds and methods provided herein include all cis- and trans-isomers and their appropriate mixtures. In certain embodiments, the compounds described herein are prepared as their individual stereoisomers by reacting a racemic mixture of the compound with an optically active resolving agent to form a pair of diastereomeric compounds / salts, separating the diastereoisomers and recovering the optically pure enantiomers. In some embodiments, the enantiomers are resolved using covalent diastereomeric derivatives of the compounds described herein. In another embodiment, the diastereoisomers are separated by separation / resolution techniques based on solubility differences. In other embodiments, the separation of stereoisomers is carried out by chromatography or by forming diastereomeric salts and separating them by recrystallization or chromatography or any combination thereof.

[0080] Pharmaceutical composition

[0081] The present disclosure also provides a pharmaceutical composition comprising at least one compound represented by Formula 1, and a pharmaceutically acceptable excipient, such as one or more excipients.

[0082] In an embodiment, the pharmaceutical compositions provided herein may further comprise an additional drug. The additional drug may have the same or similar biological effect as the compound represented by Formula 1 against the disease or disorder suffered by the individual, for example, simultaneously alleviating a certain symptom of the disease or disorder by the same mechanism of action; or may have a synergistic biological effect with the compound represented by Formula 1 against the disease or disorder suffered by the individual, for example, synergistically alleviating a certain symptom of the disease or disorder by different mechanisms of action; or may have a different biological effect independently from the compound represented by Formula 1 but play a role in preventing, alleviating or curing the disease or disorder suffered by the individual, for example, preventing an adverse reaction that may be caused by the compound represented by Formula 1 by different mechanisms of action; and so on.

[0083] As used herein, the term "excipient" may be selected from carriers, excipients, binders, suspending agents, glidants, flavoring agents, sweetening agents, disintegrants, dispersants, surfactants, lubricants, coloring agents, diluents, solubilizers, wetting agents, plasticizers, stabilizers, penetration enhancers, defoaming agents, antioxidants, preservatives, solvents or combinations thereof commonly used in the art.

[0084] As used herein, the term "carrier" refers to a pharmaceutically acceptable liquid or solid carrier or combination of carriers in a formulation that participates in carrying or transporting the active ingredient from one location, body fluid, tissue, organ (internal or external), or body part to another location, body fluid, tissue, organ, or body part. Pharmaceutically acceptable carriers are well known in the art and include, but are not limited to, sugars such as lactose, glucose, and sucrose; starches such as corn starch and potato starch; cellulose and its derivatives such as sodium carboxymethylcellulose, ethyl cellulose, and cellulose acetate; powdered tragacanth; malt; gelatin; talc; cocoa butter and suppository waxes; oils such as peanut oil, cottonseed oil, safflower oil, sesame oil, olive oil, corn oil, and soybean oil; diols such as propylene glycol; polyols such as glycerol, sorbitol, mannitol, and polyethylene glycol; esters such as ethyl oleate and ethyl laurate; agar; magnesium hydroxide and aluminum hydroxide; alginic acid; pyrogen-free water; isotonic saline; Ringer's solution; alcohols such as ethanol and propylene glycol; phosphate buffer solutions; and other non-toxic compatible substances used in pharmaceutical formulations.

[0085] As used herein, the term "excipient" generally refers to an excipient used in tablets.

[0086] As used herein, the term "diluent" refers to a substance used to dilute the active pharmaceutical ingredient prior to delivery. The diluent may also be used as a stabilizer. Non-limiting examples of diluents include starch and its processed and co-processed derivatives, sugars, disaccharides, sucrose, lactose, polysaccharides, cellulose, cellulose ethers, cellulose acetate, hydroxypropyl cellulose, sugar alcohols, xylitol, sorbitol, maltitol, lactitol; microcrystalline cellulose, magnesium carbonate or calcium carbonate or sodium carbonate, lactose, lactose monohydrate, dicalcium phosphate, compressible sugar, dibasic calcium phosphate dihydrate, mannitol, anhydrous lactose, magnesium oxide, maltodextrin, maltose, amylopectin, sodium alginate, sodium bicarbonate, calcium silicate, calcium sulfate, cell and tricalcium phosphate or a suitable combination thereof.

[0087] As used herein, the term "binder" refers to any pharmaceutically acceptable substance that can be used to bind active and inert components together to maintain cohesive and discrete parts. Non-limiting examples of binders are polyethylene glycol 12-hydroxydodecanol (SOLUTOL HS-15), polyoxyethylene hydrogenated castor oil RH40, polyethylene glycol PEG400, chitosan, hydrogenated castor oil, sodium alginate, carbomer, cellulose acetate phthalate, povidone, sugar, hydroxypropyl methyl cellulose, hydroxypropyl cellulose, starch, alginic acid, pregelatinized starch, gum arabic, gum tragacanth, ethyl cellulose, acrylic and methacrylic acid copolymers or a suitable combination thereof.

[0088] As used herein, the term "disintegrant" refers to a substance that, upon addition to a solid dosage form, promotes its decomposition or disintegration after administration and allows for the release of the active ingredient as effectively as possible to permit its rapid dissolution. Non-limiting examples of disintegrants include corn starch, sodium starch glycolate, croscarmellose sodium, crospovidone, microcrystalline cellulose, modified corn starch, sodium carboxymethyl starch, povidone, pregelatinized starch, agar, calcium or sodium carboxymethyl cellulose, colloidal silicon dioxide, chitosan, sodium docusate, hydroxypropyl cellulose, magnesium aluminum silicate, maltose, methyl cellulose, potassium polacrilate and alginic acid or a suitable combination thereof.

[0089] As used herein, the term "lubricant" refers to an excipient that is added to a powder blend to prevent the compacted powder material from adhering to the equipment during tableting or encapsulation processes. It aids in the ejection of the tablet from the die and can improve powder flow. Non-limiting examples of lubricants include magnesium stearate, stearic acid, silicon dioxide, fats, zinc stearate or sucrose stearate or sodium stearate or calcium stearate, castor oil, hydrogenated castor oil. Polyethylene glycol and its derivatives, sodium stearyl fumarate, talc or fatty acids, including lauric acid, oleic acid, glyceryl behenate, monostearin and C1-C 10 fatty acids or a suitable combination thereof.

[0090] As used herein, the term "glidant" is intended to mean a reagent used in tablet and capsule formulations to improve flowability during tablet compression and to produce an anti-caking effect. Non-limiting examples of glidants include colloidal silica, talc, fumed silica, starch, starch derivatives, and bentonite or suitable combinations thereof.

[0091] As used herein, the term "plasticizer" refers to, but is not limited to, polyols such as polyethylene glycol, propylene glycol, glycerol (glycerin), organic esters such as phthalates (diethyl ester, dibutyl ester), dibutyl sebacate, citrates (triethyl ester, acetyltriethyl ester, acetyltributyl ester), triacetin, oils / glycerides such as castor oil; acetylated monoglycerides, fractionated coconut oil or suitable combinations thereof.

[0092] In a specific embodiment, the solvent can be selected from water, acetone, chloroform, dichloromethane, ethanol, ethyl acetate, methanol, isopropanol, N,N-dimethylformamide and combinations thereof and other such substances known to those of ordinary skill in the art.

[0093] In an embodiment, the compounds and pharmaceutical compositions provided herein can be formulated into an oral solution for administration to a mammal by gavage, or can be formulated into an injection for administration to a mammal by intravenous injection, but is not limited thereto.

[0094] The compounds and pharmaceutical compositions provided herein can be formulated into a variety of pharmaceutical formulations as needed, which can be administered to a mammal, such as a human, in a variety of ways through a variety of administration routes, including but not limited to oral, parenteral (e.g., intravenous, subcutaneous, intramuscular, intramedullary injection, intrathecal, direct intraventricular, intraperitoneal, intralymphatic, intranasal injection), intranasal, oral, topical or transdermal administration routes. The pharmaceutical formulations provided herein include but are not limited to aqueous liquid dispersions, self-emulsifying dispersions, solid solutions, liposome dispersions, aerosols, solid dosage forms, powders, immediate release formulations, controlled release formulations, fast dissolve formulations, tablets, capsules, pills, delayed release formulations, extended release formulations, pulsatile release formulations, multi-particle formulations, etc.

[0095] For example, in a specific embodiment, the compounds and pharmaceutical compositions provided herein can be in a suitable dosage form and dose: (a) administered systemically to a mammal; and / or (b) administered orally to a mammal; and / or (c) administered intravenously to a mammal; and / or (d) administered to a mammal by inhalation; and / or (e) administered to a mammal by nasal administration; and / or (f) administered to a mammal by injection; and / or (g) administered topically to a mammal; and / or (h) administered to a mammal through the eye; and / or (i) administered to a mammal rectally; and so on.

[0096] The compounds and pharmaceutical compositions provided herein can also be administered in suitable dosage forms and dosages by the following regimens: (i) a single administration to a mammal; (ii) multiple administrations of the compound to a mammal over the course of a day; (iii) continuous administration to a mammal; or (iv) sequential administration to a mammal.

[0097] The compounds and pharmaceutical compositions provided herein can be administered in a therapeutically effective amount. Although human dosage levels for the compounds and pharmaceutical compositions described herein remain to be optimized, generally a therapeutically effective amount can be from about 0.25 mg / kg body weight to about 120 mg / kg body weight or more, from about 0.5 mg / kg body weight or less to about 70 mg / kg body weight, from about 1.0 mg / kg body weight to about 50 mg / kg body weight, or from about 1.5 mg / kg body weight to about 10 mg / kg body weight. For example, a therapeutically effective amount can be about 0.25 mg / kg body weight, about 0.5 mg / kg body weight, about 1.0 mg / kg body weight, about 5.0 mg / kg body weight, about 10.0 mg / kg body weight, about 50 mg / kg body weight, or about 100 mg / kg body weight. In a specific embodiment, the compounds and pharmaceutical compositions provided herein can be administered at 10 mg / kg body weight in the form of an oral solution; can also be administered at 5 mg / kg body weight in the form of an oral solution; can also be administered at 1 mg / kg body weight in the form of an injection, but not limited thereto.

[0098] Use

[0099] The present disclosure also provides the use of a compound represented by Formula 1 or a pharmaceutical composition comprising the compound represented by Formula 1 in the preparation of a medicament for treating a disease associated with reperfusion injury.

[0100] As previously described, reperfusion injury can occur in a variety of different tissues, including the heart, brain, kidney, intestine, skeletal muscle, prostate, and testis. In addition to the damage, reperfusion can also induce harmful distal effects, leading to the development of a systemic inflammatory response and multiple organ dysfunction syndrome. Most tissues can withstand short-term local ischemia that does not result in detectable injury. The length of time that a specific tissue can withstand local ischemia varies according to cell type and organ. Typically, once the critical duration of local ischemia is exceeded, cell injury and / or cell death occur. It has long been demonstrated that in many ischemia-related diseases, the clinical manifestations often deteriorate or irreversible cell death occurs after revascularization and restoration of blood circulation.

[0101] In an embodiment, the compound or pharmaceutical composition according to the present disclosure can play a protective role in an individual experiencing a disease associated with reperfusion injury.

[0102] As used herein, the term "disease associated with reperfusion injury" includes, but is not limited to, myocardial infarction, heart attack, ischemic heart disease (i.e., coronary artery stenosis and occlusion due to plaque formation, resulting in reduced blood flow and oxygen supply to the heart), heart failure resulting from ischemic heart disease, cardiac arrest, reduced arterial blood flow, stroke (e.g., obstructive stroke), transient ischemic attack, unstable angina, cerebral ischemia, peripheral vascular disease, renal failure, inflammatory disorders (e.g., rheumatoid arthritis or systemic lupus erythematosus), head trauma, drowning, sepsis, atherosclerosis, hypertension (e.g., pulmonary hypertension), drug-induced heart disease, bleeding, capillary leak syndrome (e.g., adult and pediatric respiratory distress syndrome), multiple organ system failure, low colloid osmotic pressure state (e.g., due to fasting, anorexia nervosa, or liver failure with reduced serum protein production), allergies, hypothermia, frostbite (e.g., chilblains), hepatorenal syndrome, delirium tremens, mesenteric ischemia, claudication, burns, electric shock, drug-induced vasodilation, drug-induced vasoconstriction, tissue rejection after transplantation, graft-versus-host disease, radiation exposure, pulmonary embolism, venous thrombosis, ischemic nerve disorder, ischemic nephropathy, or traumatic injury.

[0103] In embodiments, the compounds or pharmaceutical compositions according to the present disclosure can achieve at least one of the following effects after ischemia occurs: reducing the degradation of energy ester metabolism, such that lipid oxidation is attenuated; increasing the production amount of energy metabolites in the ischemic region, increasing the flux and efficiency of energy metabolism; reducing the generation and accumulation of the xanthine oxidation byproduct H2O2, reducing the occurrence of oxidative stress; etc.

[0104] For example, cerebral ischemia-reperfusion injury is a complex pathophysiological process, including oxidative stress caused by increased reactive oxygen species (ROS), calcium overload caused by increased intracellular Ca 2+ influx, inflammatory responses caused by leukocyte aggregation, etc. These mechanisms coexist and interact with each other, ultimately forming a vicious cycle leading to apoptosis and necrosis of cells. Among them, oxidative stress is an important pathway of cerebral ischemia-reperfusion injury. The oxygen consumption of brain cells accounts for about 20% of the body's oxygen consumption, and it generates sufficient adenosine triphosphate (ATP) through the mitochondrial electron transport chain to maintain cell function. Mitochondrial oxidative phosphorylation is inhibited by hypoxia, which weakens the synthesis of ATP in mitochondria and the cell energy-dependent transport process, thereby leading to the inactivation of energy-dependent Na + -Ca 2+ pump, Na + -K + pump, resulting in intracellular Ca 2+ accumulation and Na +Excretory disorders. In addition, reactive oxygen species are a series of oxygen free radicals and their derivatives produced by aerobic cells during metabolism, mainly including superoxide anion O 2- , hydrogen peroxide H2O2, and hydroxyl radical -OH. The rapid increase of reactive oxygen species can accelerate the ischemic-reperfusion injury of brain cells, including apoptosis, inflammation, and cell necrosis, etc. Inhibiting the production of reactive oxygen species can protect the brain from blood-brain barrier damage after ischemia-reperfusion. Reactive oxygen species can activate downstream pathways mediating blood-brain barrier dysfunction, such as tight junction modification, cytoskeleton reorganization, and matrix metalloproteinases (MMP), etc. Similarly, oxidative stress injury induced by reactive oxygen species will cause membrane protein damage and lipid peroxidation of the blood-brain barrier, thus increasing the permeability of the blood-brain barrier. In addition, excessive reactive oxygen species can affect the distribution and expression of occludin in the tight junctions of the blood-brain barrier, resulting in blood-brain barrier damage. Relevant experiments have proved that ROS can cause changes in the cytoskeleton through various pathways. For example, inhibiting Rho kinase and protein kinase B can relieve ROS-induced cytoskeleton reorganization, and ROS activates the ATF2 / AP-1 signaling pathway to degrade basal proteins, thus destroying the integrity of the blood-brain barrier, etc.

[0105] Studies have found that after cerebral ischemia occurs, the main energy supply metabolites inosine monophosphate IMP and AMP are significantly reduced, and the reduction in the production of energy metabolites indicates that there is an energy supply disorder. Due to the decrease in ATP production, the contents of its synthesis raw materials adenosine, inosine, and hypoxanthine increase. These metabolites help to inhibit the release of energy neurotransmitters and neuronal discharge, and can dilate blood vessels to increase nutrient supply. At the same time, these metabolites will be further converted into harmful metabolites xanthine and uric acid, and the by-product of these reactions is H2O2. The large production and accumulation of H2O2 will lead to oxidative stress and further damage to brain tissue.

[0106] In an embodiment, the compound or pharmaceutical composition according to the present disclosure can be used to treat an individual suffering from, about to suffer from, or at risk of suffering from cerebral ischemia-reperfusion injury.

[0107] In an embodiment, the compound or pharmaceutical composition according to the present disclosure can play a protective role in an individual experiencing cerebral ischemia-reperfusion injury. In one embodiment, the compound or pharmaceutical composition according to the present disclosure can reduce the degradation of energy ester metabolism after cerebral ischemia occurs, so that lipid oxidation is weakened. In another embodiment, the compound or pharmaceutical composition according to the present disclosure can increase the production of energy metabolites in the ischemic area after cerebral ischemia occurs, and improve the flux and efficiency of energy metabolism. In yet another embodiment, the compound or pharmaceutical composition according to the present disclosure can reduce the production and accumulation of the xanthine oxidation by-product H2O2 after cerebral ischemia occurs, and reduce the occurrence of oxidative stress.

[0108] Examples

[0109] The compounds of the present invention can be prepared using the reactions and techniques described below, as well as conventional techniques known to those skilled in the art of organic synthesis or variations thereof understood by those skilled in the art. Preferred methods include, but are not limited to, those described below.

[0110] The present invention is further illustrated by the following non-limiting examples that describe the preferred ways of implementing the present invention. These do not limit the scope of the present invention in any way.

[0111] Synthesis Example 1: Synthesis of Compound 1

[0112]

[0113] To a solution of catechol (20 g, 0.18 mol) in 50 ml of water, cuprous chloride (0.35 g, 3.6 mmol), 3-chloropropene (14.6 ml, 0.18 mol), and 32 ml of 14% aqueous sodium carbonate solution were added. After the addition, the mixture was stirred at room temperature for 30 minutes. Then, 20 ml of saturated brine and 40 ml of ethyl acetate were added to the reaction solution, and the mixture was extracted twice with 40 ml of ethyl acetate. The organic phase was washed with a mixed solution of saturated sodium thiosulfate and brine, and dried over anhydrous magnesium sulfate. The solvent was removed by concentration to obtain a residue, and the crude product was purified by silica gel column chromatography (ethyl acetate / petroleum ether = 1:4) to obtain a white solid (18 g, 66%), with a melting point of 45 - 46 °C.

[0114] ESI: m / z 150.9 [M+H] + 1 1H NMR (400 MHz, CDCl3) δ 6.77 (d, J = 8.0 Hz, 1H), 6.68 (d, J = 2.0 Hz, 1H), 6.61 (dd, J1 = 8.0 Hz, J2 = 2.0 Hz, 1H), 5.88 (ddt, J1 = 16.9 Hz, J2 = 10.2 Hz, J3 = 6.7 Hz, 1H), 5.20 (brs, 2H), 5.1 - 4.95 (m, 2H), 3.21 (d, J = 6.7 Hz, 2H).

[0115] Synthesis Example 2: Synthesis of Compound 2

[0116]

[0117] At room temperature, dimethyl sulfate (25.2 g, 0.2 mol) was added dropwise to a solution of eugenol (32.8 g, 0.2 mol), lithium hydroxide monohydrate (8.4 g, 0.2 mol) in 300 ml of dry tetrahydrofuran. The reaction was carried out at room temperature until completion, and the solvent was concentrated to dryness to obtain a residue. 200 ml of 5% sodium hydroxide solution was added to the residue to dissolve it, and it was extracted twice with 200 ml of ether. The organic phase was washed with 100 ml of 5% sodium hydroxide solution and 100 ml of water respectively, and the solvent was concentrated to remove to obtain a colorless or light yellow oil (33.8%, 95%).

[0118] GC-MS: M +· 178, 163 (M +· -CH3), 147 (M +· -OCH3) 1 HNMR (400 MHz, CDCl3) δ 6.79 (d, ArH, 1H), 6.65 (d, ArH, 1H), 6.58 (s, ArH, 1H), 5.86 (m, -CH2-, 2H), 5.50 (m, -CH=, 1H), 5.03 (m, =CH2, 2H), 3.78 (s, ArOCH3, 3H), 3.73 (s, ArOCH3, 3H).

[0119] Synthesis Example 3: Synthesis of Compound 3

[0120]

[0121] Bromine (25.6 g, 0.16 mol) was added dropwise to a solution of piperylene (20 g, 0.16 mol) in 100 ml of dichloromethane. After the addition was complete, the mixture was stirred at room temperature for 24 h until the raw materials reacted completely. 50 ml of water was added, and the mixture was stirred. The organic phase was washed with 50 ml of saturated sodium bicarbonate and dried over anhydrous sodium sulfate. The solvent was concentrated to remove to obtain 25.8 g of a yellow oil.

[0122] Magnesium chips (7.2 g, 0.3 mol) and 50 ml of dry THF were added to a dry three-necked flask and stirred. A small amount of bromoethane was added dropwise to initiate the reaction, and then a solution of the above yellow oil (25 g, 0.12 mol) / 50 ml of THF was added dropwise. After the addition was complete, the mixture was stirred at 50 - 60 °C for 2 h, cooled to 35 - 40 °C, and 3-bromopropene (17.4 g, 0.15 mol) was added dropwise. After the addition was complete, the temperature was raised to reflux and stirred for 2 h. 2 mol / L hydrochloric acid solution was added dropwise to quench the reaction, and the mixture was extracted with 200 ml of ethyl acetate. It was washed with 100 ml of saturated sodium bicarbonate solution and 100 ml of saturated brine, dried over anhydrous sodium sulfate, and the organic phase was concentrated to dryness to obtain a light yellow oil (13.2 g, 68%).

[0123] GC-MS: M+· 162,150 (M +· -CH3) 1 1H NMR (400 MHz, CDCl3) δ 6.80 - 6.85 (m, ArH, 3H), 5.96 (s, -CH2-, 2H), 5.92 (m, -CH=, 1H), 5.05 (dd, =CH2, 1H), 4.76 (dd, =CH2, 1H), 3.32 (d, -CH2-, 2H).

[0124] Synthesis Example 4: Synthesis of Compound 4

[0125]

[0126] To a solution of 3,4 - dimethoxyaniline (25 g, 0.16 mol), 200 ml of dichloromethane, and N,N - diisopropylethylamine (25.3 g, 0.19 mol), a solution of 3 - bromopropene (23.2 g, 0.19 mol) in 50 ml of dichloromethane was slowly added dropwise while controlling the temperature at room temperature. After the addition was complete, the mixture was stirred at the same temperature for 4 - 5 h. Then, 100 ml of water was added to the reaction solution, and the layers were separated. The organic layer was washed with 100 ml of 10% sodium carbonate solution and 100 ml of saturated brine, and then concentrated to dryness to obtain a yellow oil (22 g, 77%).

[0127] GC - MS: M +· 179.2, 165.2 (M +· -CH3) 1 1H NMR (400 MHz, CDCl3) δ 11.56 (brs, -NH, 1H), 7.11 (s, ArH, 1H), 6.87 (m, ArH, 2H), 6.44 (m, =CH-, 1H), 5.81 (d, =CH2, 1H), 4.70 (d, =CH2, 1H) 3.82 (s, -CH3, 3H) 3.77 (s, -CH3, 3H).

[0128] Synthesis Example 5: Synthesis of Compound 5

[0129]

[0130] To a solution of 3,4 - methylenedioxyaniline (20 g, 0.14 mol), 200 ml of dichloromethane, and N,N - diisopropylethylamine (22.6 g, 0.17 mol), a solution of 3 - bromopropene (21.1 g, 0.17 mol) in 50 ml of dichloromethane was slowly added dropwise while controlling the temperature at room temperature. After the addition was complete, the mixture was stirred at the same temperature for 6 h. Then, 100 ml of water was added to the reaction solution, and the layers were separated. The organic layer was washed with 100 ml of 10% sodium carbonate solution and 100 ml of saturated brine, and then concentrated to dryness to obtain a brown oil (16.3 g, 72%).

[0131] GC-MS: M +· 163.1, 149.1 (M +· -CH3) 1 1H NMR (400 MHz, CDCl3) δ 11.64 (brs, -NH, 1H), 6.87 (d, ArH, 1H), 6.56 (d, ArH, 1H), 6.37 - 6.41 (m, =CH-, ArH, 2H), 5.92 (s, -CH2, 2H), 5.81 (d, =CH2, 1H) 4.74 (d, =CH2, 1H).

[0132] Synthesis Example 6: Synthesis of Compound 6

[0133]

[0134] To a suspension of 4-allylpyrocatechol (15 g, 0.1 mol), potassium hydroxide (11.2 g, 0.2 mol), and 150 ml of chloroform, chloroacetic acid (9.5 g, 0.1 mol) was added portionwise. After addition, the temperature was raised to 50 °C and the reaction was controlled for 2 h. 50 ml of water was added to the reaction solution, and the layers were separated. The organic phase was washed with 50 ml of 5% sodium carbonate solution and 50 ml of water, concentrated to obtain an oily substance, which was directly used for the next step. A small amount of 4A molecular sieve was added, and the temperature was raised to 150 °C and stirred for 6 - 8 h. The temperature was lowered to room temperature, 100 ml of dichloromethane was added to dissolve, and it was washed with 50 ml of 5% sodium hydroxide solution and 50 ml of water respectively. The organic phase was concentrated to dryness to obtain a light yellow oily substance (10.6 g, 55.7%).

[0135] GC-MS: M +· 190.2, 150.1 (M +· -COCH3) 1 1H NMR (400 MHz, CDCl3) δ 7.33 (s, ArH, 1H), 6.87 - 7.05 (m, ArH, 2H), 5.95 (d, =CH-, 1H), 5.02 - 5.12 (m, =CH2, -CH2, 3H), 4.84 (d, =CH2, 1H), 3.32 (d, -CH2, 2H).

[0136] Synthesis Example 7: Synthesis of Compound 7

[0137]

[0138] At room temperature, to a mixed solution of 4-allylpyrocatechol (22 g, 0.14 mol), 300 ml of acetone, and cesium carbonate (47.7 g, 0.14 mol), chloromethyl isopropyl carbonate (21.3 g, 0.14 mol) was added. The mixture was kept warm and reacted overnight. The solvent was concentrated to obtain a residue. To the residue, 100 ml of saturated sodium bicarbonate solution was added, and then extracted twice with 200 ml of ethyl acetate. The organic phase was extracted with 200 ml of 1N hydrochloric acid solution. The organic phase was concentrated to dryness and purified by silica gel column chromatography with ethyl acetate / petroleum ether to obtain an oil (14.1 g, 38.1%).

[0139] GC-MS: M +· 266.1, 134.1 (M +· -(CH3)2CHOCOOCH2O) 1 1H NMR (400 MHz, CDCl3) δ 9.56 (brs, -OH, 1H), 7.22 (s, ArH, 1H), 6.88 (s, -CH2, 2H), 6.62 - 6.71 (m, ArH, 2H), 6.01 (m, =CH-, 1H) 5.09 - 5.15 (m, =CH2, -CH-, 2H), 4.78 (d, =CH2, 1H), 3.35 (d, -CH2, 2H), 1.28 (s, -CH3, 6H).

[0140] Synthesis Example 8: Synthesis of Compound 8

[0141]

[0142] At room temperature, to a mixed solution of 4-allylpyrocatechol (18.1 g, 0.12 mol), 300 ml of acetone, and cesium carbonate (39 g, 0.12 mol), chloromethyl isopropyl carbonate (18.3 g, 0.12 mol) was added. The temperature was raised to 40 - 50 °C and the mixture was kept warm and reacted for 6 - 8 h. The solvent was concentrated to obtain a residue. To the residue, 100 ml of saturated sodium bicarbonate solution was added, and then extracted twice with 200 ml of ethyl acetate. The organic phase was extracted with 200 ml of 1N hydrochloric acid solution. The organic phase was concentrated to dryness and purified by silica gel column chromatography with ethyl acetate / petroleum ether to obtain an oil (8.5 g, 26.6%).

[0143] GC-MS: M +· 266.3, 134.1 (M +· -(CH3)2CHOCOOCH2O) 1HNMR (400 MHz, CDCl3) δ 9.85 (brs, -OH, 1H), 6.87 (s, -CH2, 2H), 6.62 - 6.79 (m, ArH, 3H), 5.94 (m, =CH-, 1H), 5.06 - 5.22 (m, =CH2, -CH-, 2H), 4.74 (d, =CH2, 1H), 3.31 (d, -CH2, 2H), 1.26 (s, -CH3, 6H).

[0144] Synthesis Example 9: Synthesis of Compound 9

[0145]

[0146] To a mixed solution of eugenol (32 g, 0.19 mol), 350 ml of dichloromethane, EDCI (52.4 g, 0.27 mol), and DMAP (2.3 g, 0.019 mol), Boc-D-glutamine (56.1 g, 0.23 mol) was added. The reaction mixture was stirred at room temperature for 24 h, 100 ml of water was added, and the layers were separated. The organic phase was concentrated to dryness and directly used for the next step. To the oil, 200 ml of 48% hydrobromic acid and 200 ml of acetic acid were added, and the mixture was heated to 70 - 80 °C and kept for 5 - 6 h. After cooling to room temperature, 200 ml of dichloromethane was added for extraction. The organic phase was washed with 10% sodium carbonate solution, concentrated to dryness, and then 200 ml of dichloromethane was added to dissolve the oil. 100 ml of concentrated hydrochloric acid was added, and the mixture was stirred at room temperature for 3 - 5 h. 100 ml of water was added, and the layers were separated. The organic phase was collected and concentrated to dryness. The crude product was recrystallized from methyl tert-butyl ether to obtain a white solid powder (42.4 g, 71.1%).

[0147] LC-MS: ESI: m / z 279.1 [M + H] + 1 HNMR (400 MHz, CDCl3) δ 9.46 (s, -OH, 1H), 8.77 (s, -NH2, 2H), 6.89 - 7.15 (m, -NH2, ArH, 4H), 6.79 (d, ArH, 1H), 5.88 (m, =CH-, 1H), 4.81 - 5.16 (m, =CH2, 2H), 3.31 - 3.38 (m, -CH2, -CH-, 3H), 2.15 - 2.19 (m, -CH2, 4H).

[0148] Synthesis Example 10: Synthesis of Compound 10

[0149]

[0150] To a mixed solution of 2-methoxy-5-allylphenol (12 g, 73 mmol), 150 ml of dichloromethane, EDCI (20.1 g, 105.1 mmol), and DMAP (0.9 g, 7.3 mmol), Boc-D-glutamine (21.5 g, 87.6 mmol) was added. The reaction mixture was stirred at room temperature for 24 h. Then 100 ml of water was added, and the layers were separated. The organic phase was concentrated to dryness and directly used for the next step. To the oily substance, 200 ml of 48% hydrobromic acid and 200 ml of acetic acid were added, and the mixture was heated to 70 - 80 °C and kept for 4 - 6 h. After cooling to room temperature, 200 ml of dichloromethane was added for extraction. The organic phase was washed with 10% sodium carbonate solution, concentrated to dryness, and then 200 ml of dichloromethane was added to dissolve the oily substance. 100 ml of concentrated hydrochloric acid was added, and the mixture was stirred at room temperature for 2 - 3 h. Then 50 ml of water was added, and the layers were separated. The organic phase was collected and concentrated to dryness. The crude product was recrystallized with isopropyl ether / isopropanol to obtain a white solid powder (14.7 g, 64.3%).

[0151] LC-MS: ESI: m / z279.1[M + H] + 1 HNMR(400 MHz, CDCl3)δ9.55(s, -OH, 1H), 8.81(s, -NH2, 2H), 7.18(s,, ArH, 1H), 6.94 - 7.09(m, -NH2, ArH, 4H), 5.76(m, =CH-, 1H), 4.84 - 5.12(m, =CH2, 2H), 3.30 - 3.41(m, -CH2, -CH-, 3H), 2.12 - 2.21(m, -CH2, 4H).

[0152] Synthesis Example 11: Synthesis of Compound 11

[0153]

[0154] At room temperature, a mixed solution of 4-methylthiazole-5-carboxylic acid (21 g, 0.147 mol), HBTU (58.4 g, 0.15 mol), DIPA (32.5 g, 0.25 mol), DMAP (1.7 g, 0.014 mol), 25 ml of DMSO, and 225 ml of DMF was stirred and reacted for 1 h. Then, eugenol (23.2 g, 0.14 mol) was added, and the mixture was continuously stirred and reacted at room temperature for 24 h. 100 ml of water was added thereto, and the solvent was removed by reduced pressure concentration with water. The residue was dissolved in 300 ml of DCM, washed twice with 150 ml of water each time, and dried over molecular sieves. It was filtered off and directly used for the next reaction. The DCM sample solution was cooled to -50 °C to -60 °C, and boron tribromide (87.7 g, 0.35 mol) was added dropwise under nitrogen protection. After the addition was complete, the temperature was slowly raised to room temperature and the reaction was kept for 1 - 2 h. 200 ml of methanol was slowly added dropwise at low temperature, and the mixture was stirred for 30 min. The solvent was removed by concentration, and the product was purified by silica gel column chromatography with ethyl acetate / petroleum ether to obtain an off-white solid (21.2 g, 55.2%).

[0155] LC-MS: ESI: m / z276.1[M + H] + 1 HNMR(400MHz, DMSO-d6)δ9.66(s, N=CH-, 1H), 9.44(brs, -OH, 1H),6.94~6.99(m, ArH, 2H), 6.62(d, ArH, 1H), 5.83(m, =CH-, 1H), 4.81~5.13(m, =CH2, 2H), 3.30(d, -CH2, 2H), 2.44(s, -CH3, 3H).

[0156] Synthesis Example 12: Synthesis of Compound 12

[0157]

[0158] At room temperature, a mixed solution of 4-methylthiazole-5-carboxylic acid (8.34 g, 58.3 mmol), HBTU (24 g, 63.5 mmol), DIPA (13.67 g, 105.8 mmol), DMAP (0.65 g, 5.3 mmol), 10 ml of DMSO and 90 ml of DMF was stirred for 1 h, then 2-methoxy-5-allylphenol (8.7 g, 52.9 mmol) was added, and the reaction was continued to stir at room temperature for 24 h. 30 ml of water was added thereto, and the solvent was removed by reduced pressure concentration with water. The residue was dissolved in 100 ml of DCM, washed twice with 50 ml of water each time, and dried over molecular sieve. It was filtered and directly used for the next reaction. The DCM sample solution was cooled to -50 °C to -60 °C, and boron tribromide (33.1 g, 132.2 mmol) was added dropwise under nitrogen protection. After the addition was completed, it was slowly warmed to room temperature and kept warm for 2 h. 50 ml of methanol was slowly added dropwise at low temperature, stirred for 30 min, the solvent was concentrated and removed, and purified by silica gel column chromatography with ethyl acetate / petroleum ether to obtain an off-white solid (6.81 g, 46.8%).

[0159] LC-MS: ESI: m / z276.4[M+H] + 1 HNMR(400MHz, DMSO-d6)δ9.68(s, N=CH-, 1H), 9.42(brs, -OH, 1H),7.17(s, ArH, 1H), 6.71~6.76(m, ArH, 2H), 5.88(m, =CH-, 1H), 4.86~5.18(m, =CH2, 2H), 3.36(d, -CH2, 2H), 2.45(s, -CH3, 3H).

[0160] Synthesis Example 13: Synthesis of Compound 13

[0161]

[0162] To a mixed solution of 4-allylpyrocatechol (15.1 g, 0.1 mol), anhydrous potassium carbonate (27.6 g, 0.2 mol), 120 ml of acetonitrile and 30 ml of dichloromethane, 4-hydroxymethylphenylboronic acid (13.6 g, 0.09 mol) was added. After the addition was completed, the temperature was raised to 50 - 60 °C and stirred for 6 - 8 h, filtered, the organic phase was washed twice with 50 ml of saturated sodium bicarbonate solution each time, washed with 50 ml of saturated brine, the organic phase was concentrated to dryness, and the crude product was purified by silica gel column chromatography with methanol / dichloromethane to obtain an off-white solid (14.8 g, 61.8%).

[0163] LC-MS: ESI: m / z267.3[M+H] + 1HNMR (400 MHz, CD3OD) δ 7.76 (d, ArH, 2H), 7.22 (d, ArH, 2H), 7.16 (s, ArH, 1H), 6.52 - 6.70 (m, ArH, 2H), 5.86 (m, =CH-, 1H), 5.26 (brs, -OH, 1H), 4.96 - 5.05 (m, =CH2, 2H), 4.67 (s, -CH2, 2H), 3.32 (d, -CH2, 2H).

[0164] Synthesis Example 14: Synthesis of Compound 14

[0165]

[0166] To a mixed solution of 4-allylpyrocatechol (9 g, 0.06 mol), 100 ml of chloroform, and 4-methoxyphenylboronic acid (8.3 g, 0.05 mol), 0.8 g of DOWEX (ion exchange resin) was added. The temperature was raised to 50 - 60 °C and stirred for 3 - 5 h. Then it was cooled to room temperature and filtered. The organic phase was washed twice with 50 ml of sodium bicarbonate solution and then with 50 ml of saturated brine. The organic phase was concentrated to dryness, and the crude product was recrystallized from ethyl acetate / n-hexane to obtain an off-white solid (9.27 g, 66.2%).

[0167] LC-MS: ESI: m / z 280.9 [M + H] + 1 HNMR (400 MHz, CD3OD) δ 7.84 (d, ArH, 2H), 7.26 (d, ArH, 2H), 6.85 (s, =CH-, 1H), 6.51 - 6.65 (m, ArH, 2H), 5.94 (m, =CH-, 1H), 5.08 (d, =CH2, 1H), 4.77 - 4.81 (m, =CH2, -CH2, 3H), 3.35 (d, -CH2, 2H), 3.26 (s, -CH3, 3H).

[0168] Synthesis Example 15: Preparation of Compound 15

[0169]

[0170] 4-Allylpyrocatechol (9.3 g, 0.062 mol), 200 ml of toluene, and 4-acetoxymethylphenylboronic acid (12.2 g, 0.062 mol) were successively added to a dry three-necked flask equipped with a water separator. The temperature was raised to about 110 °C and refluxed for 24 h. The solvent was removed under reduced pressure, and the residue was obtained after cooling to room temperature. The crude product was recrystallized from ethyl acetate / isopropyl ether to obtain an off-white solid (13.8 g, 72.3%).

[0171] LC-MS: ESI: m / z 309.2 [M+H] + 1 HNMR (400 MHz, CD3OD) δ 7.88 (d, ArH, 2H), 7.28 (d, ArH, 2H), 6.83 (s, =CH-, 1H), 6.55~6.67 (m, ArH, 2H), 5.96 (m, =CH-, 1H), 5.22 (s, -CH2, 2H), 4.74~4.85 (m, =CH2, 2H), 3.37 (d, -CH2, 2H), 2.10 (s, -CH3, 3H).

[0172] Synthesis Example 16: Preparation of Compound 16

[0173]

[0174] 4-Bromomethylphenylboronic acid pinacol ester (1.2 g, 4.0 mmol), 4-allylpyrocatechol (0.42 g, 2.8 mmol), N,N-diisopropylethylamine (0.72 g, 5.6 mmol), and 20 ml of diethylene glycol dimethyl ether were successively added to a three-necked flask. The temperature was raised to 130~140 °C and the mixture was kept warm for reaction for 3~4 h. Then it was cooled to room temperature, 100 ml of water was added, and the mixture was filtered to obtain a crude solid. The crude product was purified by a methanol / dichloromethane silica gel column to obtain a white solid (430 mg, 42.1%).

[0175] LC-MS: ESI: m / z 367.0 [M+H] + 1 HNMR (400 MHz, CD3OD) δ 9.88 (brs, -OH, 1H), 7.81 (d, ArH, 2H), 7.24 (d, ArH, 2H), 6.82~6.78 (m, ArH, 3H), 5.90 (m, =CH-, 1H), 5.15 (s, -CH2, 2H), 4.82~4.95 (m, =CH2, 2H), 3.38 (d, -CH2, 2H), 1.25 (s, -CH3, 12H).

[0176] Synthesis Example 17: Preparation of Compound 17

[0177]

[0178] 4-Bromomethylphenylboronic acid pinacol ester (1.1 g, 3.7 mmol), 4-allylpyrocatechol (0.55 g, 3.7 mmol), triethylamine (0.56 g, 5.5 mmol), and 20 mL of ethylene glycol dimethyl ether were successively added to a three-necked flask. The temperature was raised to reflux and the reaction was maintained for 5 - 6 h. After cooling to room temperature, 100 mL of water was added, and the mixture was filtered to obtain a crude solid. The crude product was purified by a silica gel column with methanol / dichloromethane to obtain a white solid (790 mg, 58.4%).

[0179] LC-MS: ESI: m / z 367.3 [M+H] + 1 HNMR (400 MHz, CD3OD) δ 9.48 (brs, -OH, 1H), 7.88 (d, ArH, 2H), 7.27 (d, ArH, 2H), 6.72 - 6.98 (m, ArH, 3H), 5.84 (m, =CH-, 1H), 5.11 (s, -CH2, 2H), 4.84 - 4.97 (m, =CH2, 2H), 3.35 (d, -CH2, 2H), 1.22 (s, -CH3, 12H).

[0180] Synthesis Example 18: Preparation of Compound 18

[0181]

[0182] While controlling the temperature at 0 - 5 °C, 1 mL of 4N hydroxide solution and 18.2 g of sulfur trioxide-trimethylamine copolymer were added to a mixed solution of 4-allylpyrocatechol (12.3 g, 82 mmol) and 120 mL of DMF. The temperature was raised to room temperature and the mixture was stirred for 2 h. Subsequently, 1 mL × 4 of 4N hydroxide solution and 18.2 g × 4 of sulfur trioxide-trimethylamine copolymer were added in batches until the reaction was complete. The solvent was concentrated and removed. 200 mL of dichloromethane and 100 mL of water were added and stirred for extraction. The organic phase was concentrated to dryness to obtain a crude product (13.4 g, 58.7%).

[0183] 13 g of the above crude solid was added to a three-necked flask, and 150 mL / 150 mL / 300 mL of ethyl acetate / 2-butanone / water was added and stirred to dissolve. 300 mL of 1N sulfuric acid solution was added dropwise, and the mixture was stirred at room temperature for 2 - 3 h. It was neutralized with 1N sodium hydroxide solution, and the solvent was removed by reduced pressure concentration to obtain a crude residue. It was purified by a silica gel column with (ethyl acetate / acetic acid = 30:1) to obtain a white solid (5.6 g, 56%).

[0184] LC-MS: ESI: m / z 215.0 [M+H] + 1HNMR (400 MHz, CD3OD) δ 10.16 (brs, -OH, 1H), 7.32 - 7.66 (m, ArH, 3H), 5.87 (m, =CH-, 1H), 4.84 - 5.08 (m, =CH2, 2H), 4.54 (brs, -OH, 1H), 3.38 (d, -CH2, 2H).

[0185] Example 1: Identification of in vivo metabolites

[0186] Weigh an appropriate amount of Compound 1 and place it in a 5 mL brown glass bottle. Add methanol and dissolve it by ultrasonic treatment to prepare a test solution with a concentration of 1.00 mg / mL. Prepare it freshly before use. Take 100 μL of the 1.00 mg / mL test solution and serially dilute it to 1000 ng / mL with a diluent (methanol: water = 1:1, V / V).

[0187] Take 50 μL of plasma samples at different sampling time points, add 200 μL of acetonitrile, vortex for 5 min, centrifuge at 14000 rpm for 5 min, then take 150 μL of the supernatant and mix it evenly, and store it at -80 °C for later use. The selected SD rats were prepared with samples according to the above method, with 3 replicates for the intragastric administration group and 3 replicates for the intravenous injection administration group, a total of 6 plasma samples.

[0188] The sample before administration was used as a blank control and prepared according to the sample preparation method.

[0189] The above samples were evaporated to dryness of the solvent using a nitrogen blower, then added 100 μL of a reconstitution solvent of acetonitrile - water (50:50), vortexed for 5 min, centrifuged at 14000 rpm for 5 min, and then the supernatant was taken for LC - HRMS / MS determination.

[0190] Using LC - HRMS / MS technology, a total of 7 metabolites of Compound 1 were identified in the plasma samples of the intragastric administration group and the intravenous injection administration group of SD rats. The content distribution of Compound 1 and its metabolites is as Figure 1 shown. Among them, 7 metabolites (M1, M2, M3, M4, M5, M6, M7) were identified in the plasma of SD rats in the intragastric administration group; 7 metabolites (M1, M2, M3, M4, M5, M6, M7) were identified in the plasma of SD rats in the intravenous injection administration group; According to the speculated metabolite structures, the metabolic pathway of Compound 1 in SD rats is as Figure 1 shown, where the table data are mass percentages.

[0191] Example 2: In vivo pharmacokinetics

[0192] The contents of Compound 1 and its main metabolites (M4 (m / z = 229.0176), M5 (m / z = 231.0333), M7 (m / z = 325.0929)) were determined. The bioavailability and other pharmacokinetic characteristics of Compound 1 in SD rats were evaluated.

[0193] 2.1 Preparation of animal administration solutions

[0194] Gavage administration group: Weigh 31.11 mg of the test substance of Compound 1, dissolve it in normal saline to obtain an oral liquid of Compound 1, and the drug preparation concentration is 5.00 mg / mL. Prepare it immediately before use.

[0195] Intravenous injection administration group: Weigh 26.80 mg of the test substance of Compound 1, dissolve it in normal saline to obtain an injection liquid of Compound 1, and the drug preparation concentration is 5.00 mg / mL. Prepare it immediately before use.

[0196] 2.2 In vivo experiments

[0197] The experimental SD rats were divided into 2 groups, with 3 rats in each group (gavage administration, administration dose 10 mg / kg; intravenous injection administration, administration dose 5 mg / kg), and a single dose was administered. Blood samples were collected before administration, 0.083 h, 0.25 h, 0.5 h, 1 h, 2 h, 4 h, 6 h, 8 h, and 24 h after administration.

[0198] Blood sample collection and treatment: Collect 1.0 mL of blood from the posterior limb vein, add it to a heparin sodium-containing centrifuge tube pre-cooled with ice water, place it in an ice bath, let it stand and then centrifuge (4000 rpm, 10 min), take the upper plasma, place it in a sterile EP tube, and store it at -80 °C for later use.

[0199] 2.3 Sample treatment

[0200] Add blank samples (DB) (50 μL of blank SD rat plasma + 10 μL of 50% methanol aqueous solution); control samples (Blank) (50 μL of blank SD rat plasma + 10 μL of internal standard working solution (sodium diclofenac, 50 ng / mL)); and test samples (50 μL of the sample to be tested + 10 μL of internal standard working solution (sodium diclofenac, 50 ng / mL)) to 150 μL of acetonitrile, vortex and mix well, centrifuge at 14000 rpm for 5 min at 4 °C, take 150 μL of the supernatant for injection, and perform LC-MS / MS analysis.

[0201] In all experiments, Compound 1 was not detected in the plasma of SD rats. The detected peak areas of the three metabolites are shown in Figures 2A to 2F as follows.

[0202] Example 3. Protective effect on cerebral ischemia-reperfusion injury

[0203] 3.1 Basic Information of the Experiment

[0204] 3.1.1 Animal Strain: SD rats: SPF grade, male, body weight 240 - 260 g, 40 rats.

[0205] 3.1.2 Grouping and Dosage:

[0206] Sham operation group: Underwent the same operation, without embolization, given the same volume of solvent.

[0207] Model group: Reperfusion was performed 2.0 h after infarction, given the same volume of solvent.

[0208] Test drug group: Compound 1, dosage 10 mg / kg, equivalent to 12 times the clinical dose (calculated based on the daily intravenous infusion dose of 50 mg for a 60 - kg human body weight).

[0209] 3.2 Model Preparation and Drug Administration

[0210] 3.2.1 Establishment of Rat Cerebral Ischemia - Reperfusion Model (Thread Embolization Method)

[0211] After weighing the rats, they were anesthetized with isoflurane using an anesthesia machine. The body temperature of the animals was maintained at 36.5 °C using a heating plate. The rats were fixed, the neck hair was shaved, and disinfected with iodophor, and then de - iodinated with 75% alcohol. A median incision was made along the ventral side of the neck, the right common carotid artery was separated, the sternocleidomastoid muscle and hyoglossus muscle were separated bluntly to avoid stimulating the vagus nerve during the operation. The external carotid artery was separated upward and ligated. The thyroid artery and superior pharyngeal artery were separated bluntly, coagulated with a high - frequency electrocautery, and cauterized; and the external carotid artery was cut at the distal end. The internal carotid artery was separated bluntly from the vagus nerve and glossopharyngeal nerve, and the pterygomandibular artery was ligated. The blood circulation of the common carotid artery and internal carotid artery was blocked with an arterial clip. An incision was made at the external carotid artery, and a pre - treated thread embolism was inserted. It was introduced into the internal carotid artery at the bifurcation of the common carotid artery until the middle cerebral artery was blocked. The insertion depth was about 18 - 22 mm (from the bifurcation), and the insertion depth of the sham operation was 10 mm without blocking the middle cerebral artery. The skin was sutured; 2 h after embolization, the rats were anesthetized again, the incision was opened, the thread embolism was gently pulled out to achieve reperfusion, and the skin was sutured.

[0212] 3.2.2 Drug Administration Method and Administration Cycle

[0213] After the rats were awake after reperfusion, neurological function scores were performed. The selected animals were randomly grouped (9 rats in the sham operation group, 12 rats in the model group, and 12 rats in the test drug group), and administered by tail vein injection (dosage as above). 0.5 ml / 100 g, once a day for 10 consecutive days.

[0214] 3.3 Detection Indexes

[0215] General growth of animals: The animals were weighed before drug administration, and then weighed every 3 days thereafter.

[0216] Zea longa Neurological Function Score: At 6 h after embolization in rats, the Zea longa neurological function score was performed. Scoring criteria: 0 point: no symptoms of neurological deficit; 1 point: mild neurological deficit, unable to fully extend the left forepaw; 2 points: moderate focal neurological deficit, circling to the left; 3 points: severe focal neurological deficit, falling to the left; 4 points: unable to walk spontaneously, with a decreased level of consciousness.

[0217] TTC Staining Examination of Brain Tissue: After the rats were anesthetized, they were perfused with 50 ml of physiological saline pre-cooled at 4°C through the heart, and then the rat brains were carefully removed and frozen in an -80°C refrigerator for 3 min; they were longitudinally cut into 2-mm-thick slices using a brain tissue sectioning mold and stained with 2% TTC staining solution at 37°C for 30 min; fixed with 4% paraformaldehyde for 24 h; the infarction area of each transverse brain slice was observed (the infarction area appeared white, and the normal area was red), and photographs were taken. The total infarction volume of the rat brains was calculated.

[0218] Animal Mortality: Record the survival status of the animals after drug administration.

[0219] Table 1 shows the weight changes of SD rats in each group after drug administration. After modeling, the body weights of the rats in the model group significantly decreased. Among them, the weight decreases on the 4th and 7th days were significant compared with those in the sham operation group; compared with the model group, there was no significant difference in the weight decrease of the rats in the test drug group, and there was a further downward trend in weight on the 7th and 10th days, indicating that the drug may have an impact on the body weight growth of animals.

[0220] Table 1. Weight Changes of SD Rats in Each Group after Drug Administration.

[0221]

[0222] Table 2 shows the Zea longa neurological function scores of rats in each group. Before drug administration, after animal modeling, they were randomly grouped according to the scores. There was no difference in the neurological function scores between the model group and the test drug group; after drug administration, the comparison of the neurological function scores between the test drug group and the model group showed a downward trend, but there was no statistically significant difference. The results indicate that the drug has a potential improvement effect on the neurological function of rats with brain injury.

[0223] Table 2. Zea longa Neurological Function Scores of Rats in Each Group.

[0224]

[0225] Table 3 shows the infarction volumes of the brains of SD rats in each group. Compared with the sham operation group, the rats in the model group showed a significant infarction volume in the brain; compared with the model group, the infarction volume of the brains of the animals in the test drug group was significantly reduced, and the reduction was statistically significant (one-way ANOVA). The results indicate that intravenous administration of Compound 1 for 10 days has a significant effect on improving the infarction volume of the MACO-induced cerebral infarction in rats.

[0226] Table 3. Infarction volumes of the brains of SD rats in each group.

[0227]

[0228] Table 4 shows the survival of SD rats in each group. The survival rate of the model group was 75%; compared with the model group, there was no significant difference in the survival time of the rats in the test drug group, but the survival rate decreased to 66.7%, indicating that when Compound 1 was intravenously administered at a dose of 10 mg / kg, there may be certain toxic and side effects.

[0229] Table 4. Survival of SD rats in each group.

[0230]

[0231] The neurological function score and infarction volume of animals are important evaluation indicators for cerebral ischemia-reperfusion injury. The results of this study showed that intravenous administration of Compound 1 for 10 days had a downward trend in the neurological function score of rats with cerebral infarction and had a significant effect on reducing the infarction volume of the brains of model rats. The results indicate that Compound 1 has a certain effect on improving the neurological function and infarction volume of rats with brain injury.

[0232] The body weight and survival rate of rats reflect the influence of the model conditions and drugs on the general growth of mice. The results of this study showed that after modeling, the body weight of the model rats decreased significantly. Compound 1 had no significant difference in the decrease of the body weight of the model mice, and there was a further downward trend in the body weight on the 7th and 10th days, suggesting that the drug may have an impact on the body weight growth of animals.

[0233] Example 4. In vivo efficacy study

[0234] 4.1 Basic information of the experiment

[0235] Animal strain: SD rats Test article: Compound 1, dose 10 mg / kg.

[0236] 4.2 Model preparation and drug administration

[0237] 4.2.1 Model preparation

[0238] After being anesthetized with isoflurane, the rats were placed supine on a thermostatic plate, with their body temperature maintained at 37±0.5°C, and then fixed on the operating table. The skin was incised along the midline of the neck, and the right common carotid artery (CCA), external carotid artery (ECA), and internal carotid artery (ICA) were carefully dissected. The ECA was ligated and transected, and then straightened to be in a straight line with the ICA. A small incision was made on the ECA, and a round-tipped siliconized suture with a length of 4.0 cm and a diameter of 0.26 mm was inserted into the ICA through this opening for about 1.6 cm until the origin of the anterior cerebral artery of the rat, blocking the blood supply to the middle cerebral artery. The opening of the ECA was ligated and the surgical incision was sutured.

[0239] 4.2.2 Drug administration protocol (3 rats per group)

[0240] Sham operation group: SD rats were perfused 7 days after sham operation for animal tissue sampling.

[0241] Model group: Animal tissue sampling was directly carried out 7 days after cerebral ischemia-reperfusion MCAO modeling.

[0242] Test drug group (iv. administration: 10 mg / kg): After cerebral ischemia-reperfusion MCAO modeling, cerebral ischemia for 1.5 h and reperfusion for 24 h, animal tissue sampling was directly carried out after iv administration. There were brain samples administered for 7 consecutive days.

[0243] 4.3 Data measurement

[0244] Airflow-assisted desorption electrospray ionization (AFADESI) ion source and Orbitrap mass spectrometer were used to perform mass spectrometry imaging analysis on the brain slices of rats in the sham operation group, model group, and test drug group. Using spatial resolution metabolomics methods, differential ions before and after drug administration were screened by methods such as OPLS-DA, t-test, and pathway enrichment analysis, and the differential ions were analyzed and identified.

[0245] The AFADESI-MSI technology can highly sensitively and comprehensively detect the in-situ distribution and content information of metabolites in tissues. In this study, full-scan mass spectrometry imaging analysis in positive and negative ion modes was performed on the brain tissue slices of rats in the sham operation group, model group, and test drug group, and thousands of ion mass spectrometry information of metabolites were obtained for each group. Metabolites include multiple types such as amino acids, organic acids, phospholipids, choline, and fatty acids. The results of mass spectrometry imaging analysis of rat brain tissue gave the spatial distribution information of these metabolites in the brain microregions.

[0246] It was found that the metabolism of fatty acids (such as m / z 253.2168) and glycerides (such as m / z 509.2867) was significantly up-regulated in the ischemic area of the model group, while the metabolism of phospholipids (such as m / z 888.6211) was significantly down-regulated in the ischemic area, indicating that the degradation of such energy lipid metabolism was severe after ischemia and lipid oxidation was exacerbated. After administration, it was found that the generation of fatty acids and glycerides and the degradation metabolism of phospholipids were weakened, and lipid oxidation was weakened, suggesting that Compound 1 had a certain protective effect on lipid metabolism. It was speculated that Compound 1 might act on reactive oxygen species such as H2O2, a by-product of oxidative stress, reduce the generation and accumulation of reactive oxygen species, and reduce the occurrence of oxidative stress, thereby playing a certain protective role against brain damage.

[0247] The study also found that purine metabolism was significantly down-regulated in the normal tissue area and ischemic area of the model group, with significant decreases in the main energy supply metabolites inosine monophosphate IMP and AMP, and increases in the contents of uric acid and xanthine in the ischemic area, suggesting that the generation of such energy metabolites decreased after ischemia and energy supply was impaired. Due to the decrease in ATP generation, the contents of its synthesis raw materials adenosine, inosine, and hypoxanthine increased. These metabolites helped to inhibit the release of energy neurotransmitters and neuronal discharge, and could dilate blood vessels to increase nutrient supply. At the same time, these metabolites would be further converted into harmful metabolites xanthine and uric acid, and the by-product of these reactions was H2O2. The large generation and accumulation of H2O2 would lead to the occurrence of oxidative stress and further damage to the brain tissue. After administration, it was found that the energy supply metabolites IMP and AMP increased significantly in the normal tissue area and slightly in the ischemic area, and the contents of uric acid and xanthine increased in the ischemic area, suggesting that Compound 1 might improve the flux and efficiency of energy metabolism. From the changes in hypoxanthine and purine metabolism, no obvious metabolic inhibitory effect was observed, and it might not have an inhibitory effect on xanthine oxidase. However, it was speculated that Compound 1 might act on the by-product H2O2 of xanthine oxidation, reduce the generation and accumulation of H2O2, and reduce the occurrence of further oxidative stress, thereby playing a certain protective role against brain damage.

[0248] Example 5. In vitro efficacy study

[0249] Mouse hippocampal neuron HT22 cells were taken and resuspended in DMEM complete medium containing 10% fetal bovine serum. According to 7.5×10 4Cells were seeded at a density of 50 per well in a 96-well plate. A normal control group (cells + complete medium) and experimental groups containing different concentrations of the compound (0, 0.3125, 0.625, 1.25, 2.5, 5, 10, 20 μM) were established, with 3 replicate wells in each group. Except for the control group, sodium dithionite (Na2S2O4) with a final concentration of 1 mM was added to the experimental groups and incubated in a 5% CO2, 37 °C incubator for 1 h to prepare an oxygen-deficient injury model. After model preparation, the experimental groups were replaced with fresh complete medium, and the corresponding concentrations of the compound were added to the cells in the experimental groups. After culturing the cells in a 5% CO2, 37 °C incubator for 24 h, 10 μL of CCK8 solution was added to each well and cultured in the incubator for 2 h. The absorbance (A) value of each well was measured at a wavelength of 450 nm using a microplate reader, and the cell survival rate was calculated and the EC 50 was calculated. The results are shown in Table 5 as follows.

[0250] Table 5

[0251]

[0252]

[0253] As can be seen from the above, the compounds in this article are all in the same order of magnitude and achieve excellent half-maximal effective concentration.

[0254] Although the present invention has been described in terms of its specific embodiments, certain modifications and equivalents will be apparent to those skilled in the art and are intended to be included within the scope of the present invention.

Claims

1. Use of a compound represented by Formula 1 or a pharmaceutically acceptable salt or stereoisomer thereof in the preparation of a medicament for treating a disease associated with reperfusion injury, wherein: X is carbon or nitrogen; R1 and R2 are the same as or different from each other, and each independently is an unsubstituted or at least one R 10a substituted hydroxy group, an unsubstituted or at least one R 10a substituted sulfo group, an unsubstituted or at least one R 10a substituted C1-C 10 alkoxy group, an unsubstituted or at least one R 10a substituted C1-C 10 alkyl acyloxy group, an unsubstituted or at least one R 10a substituted C1-C 10 alkylsulfonyl group, an unsubstituted or at least one R 10a substituted C3-C 12 cycloalkyloxy group, an unsubstituted or at least one R 10a substituted C3-C 12 cycloalkyl acyloxy group, an unsubstituted or at least one R 10a substituted C3-C 12 cycloalkylsulfonyl group, an unsubstituted or at least one R 10a substituted C4-C 13 cycloalkylalkoxy group, an unsubstituted or at least one R 10a substituted C6-C 20 aryloxy group, an unsubstituted or at least one R 10a substituted C6-C 20 aryl acyloxy group, an unsubstituted or at least one R 10a substituted C6-C 20 arylsulfonyl group, an unsubstituted or at least one R 10a substituted C7-C 21 arylalkoxy group, an unsubstituted or at least one R 10a substituted C2-C 12 heterocyclyloxy group, an unsubstituted or at least one R 10a substituted C2-C 12 heterocyclic acyloxy group, an unsubstituted or at least one R 10a substituted C2-C 12 heterocyclic sulfonyl group, an unsubstituted or at least one R 10a substituted C3-C 13 heterocyclic alkoxy group, an unsubstituted or at least one R 10a substituted C2-C 10 carbonate alkoxy group, or an unsubstituted or at least one R 10a substituted glutamine group, and R1 and R2 are optionally bonded to each other to form a heterocyclic group containing at least two oxygen atoms as ring-forming atoms, wherein said R 10a is selected from deuterium; halogen; oxo; acylamino; formyloxy; acetoxy; C1-C6 alkyl group; C1-C6 alkoxy group; C6-C 12 aryl group which is unsubstituted or substituted by hydroxy, formyloxy, acetoxy, C1-C6 alkyl or C1-C6 alkoxy; C7-C 13 aralkyl group which is unsubstituted or substituted by hydroxy, formyloxy, acetoxy, C1-C6 alkyl or C1-C6 alkoxy; C2-C 12 heterocyclic group.

2. The use according to claim 1, wherein R1 and R2 are bonded to each other to form an unsubstituted or at least one R- 10a substituted C2-C 12 dioxolanyl group, an unsubstituted or at least one R- 10a substituted C2-C 12 dioxaborolanyl group, an unsubstituted or at least one R- 10a substituted C2-C 12 dioxazanyl group, or an unsubstituted or at least one R- 10a substituted C2-C 12 dioxathiolanyl group; Preferably, R1 and R2 are bonded to each other to form an unsubstituted or at least one R- 10a substituted dioxolanyl group, an unsubstituted or at least one R- 10a substituted dioxanyl group, an unsubstituted or at least one R- 10a substituted dioxaborolanyl group, or an unsubstituted or at least one R- 10a substituted dioxaboranyl group; wherein R 10a is as defined in claim 1.

3. The use according to claim 1, wherein R1 and R2 are each independently a hydroxyl group; a sulfo group; a C1-C 10 alkoxy group; a glutamine group; a C2-C 12 heterocyclic acyloxy group optionally substituted by C1-C6 alkyl; a C7-C 12 arylalkoxy group optionally substituted by a C2-C 21 heterocyclic group optionally substituted by C1-C6 alkyl; a C2-C 10 carbonate alkoxy group; or R1 and R2 are bonded to each other to form an optionally oxo, formyloxy, acetoxy, C1-C6 alkyl, C1-C6 alkoxy, optionally C6-C substituted by C1-C6 alkoxy12 An aryl group, a C7-C optionally substituted by a C1-C6 alkoxy 13 An aralkyl group, or a dioxolanyl group, a dioxanyl group or a dioxaborolanyl group substituted by a heterocyclic group optionally substituted by a hydroxy group, a formyloxy group, an acetyloxy group, a C1-C6 alkyl group or a C1-C6 alkoxy group; 12 Preferably, R1 and R2 are each independently: Or R1 and R2 are bonded to each other to form: Wherein, * and *' each represent a binding site to an adjacent atom on the benzene ring.

4. The use according to any one of claims 1 to 3, wherein the compound represented by formula 1 is selected from the following compounds 1 to compound 18:

5. A compound represented by formula 1: Or a pharmaceutically acceptable salt or stereoisomer thereof, Wherein: X is carbon or nitrogen; R1 and R2 are the same or different from each other and are each independently a 10a A substituted hydroxyl group, an unsubstituted or substituted hydroxyl group 10a substituted sulfo group, unsubstituted or replaced by at least one R 10a Substituted C1-C 10 Alkoxy groups, unsubstituted or substituted with at least one R 10a Substituted C1-C 10 Alkyl acyloxy group, unsubstituted or substituted with at least one R 10a Substituted C1-C 10 Alkylsulfonyl groups, unsubstituted or substituted with at least one R 10a Substituted C3-C 12 Cycloalkyloxy groups, unsubstituted or substituted with at least one R 10a Substituted C3-C 12 Cycloalkylacyloxy groups, unsubstituted or substituted with at least one R 10a Substituted C3-C 12 Cycloalkylsulfonyl groups, unsubstituted or substituted with at least one R 10a Substituted C4-C 13 Cycloalkylalkoxy groups, unsubstituted or substituted with at least one R 10a Substituted C6-C 20 Aryloxy groups, unsubstituted or substituted with at least one R 10a Substituted C6-C 20 Aryl acyloxy group, unsubstituted or substituted with at least one R 10a Substituted C6-C 20 Arylsulfonyl groups, unsubstituted or substituted with at least one R 10a Substituted C7-C 21 Arylalkoxy groups, unsubstituted or substituted with at least one R 10a Substituted C2-C 12 Heterocyclyloxy group, unsubstituted or substituted with at least one R 10a Substituted C2-C 12 Heterocyclyl acyloxy group, unsubstituted or substituted with at least one R 10a Substituted C2-C 12 Heterocyclylsulfonyl group, unsubstituted or substituted with at least one R 10a Substituted C3-C 13 Heterocyclylalkoxy group, unsubstituted or substituted with at least one R 10a Substituted C2-C 10 carbonate alkoxy group, either unsubstituted or substituted with at least one R 10a a substituted glutamine group, and R1 and R2 are optionally bonded to each other to form a heterocyclic group containing at least two oxygen atoms as ring-forming atoms, wherein said R 10a is selected from deuterium; halogen; oxo; acylamino; formyloxy; acetoxy; C1-C6 alkyl group; C1-C6 alkoxy group; C6-C 12 aryl group which is unsubstituted or substituted by hydroxy, formyloxy, acetoxy, C1-C6 alkyl or C1-C6 alkoxy; C7-C 13 aralkyl group which is unsubstituted or substituted by hydroxy, formyloxy, acetoxy, C1-C6 alkyl or C1-C6 alkoxy; C2-C 12 heterocyclic group.

6. The compound according to claim 5, wherein R1 and R2 are bonded to each other to form an unsubstituted or at least one R-substituted C2-C 10a substituted C2-C 12 dioxolanyl group, an unsubstituted or at least one R-substituted C2-C 10a substituted C2-C 12 dioxaborolanyl group, an unsubstituted or at least one R-substituted C2-C 10a substituted C2-C 12 dioxazanyl group, or an unsubstituted or at least one R-substituted C2-C 10a substituted C2-C 12 dioxathiolanyl group; Preferably, R1 and R2 are bonded to each other to form an unsubstituted or at least one R-substituted dioxolanyl group, an unsubstituted or at least one R-substituted 10a dioxolanyl group, an unsubstituted or at least one R-substituted 10a ​A substituted dioxanyl group, an unsubstituted or at least one R- 10a substituted dioxaborolanyl group, or an unsubstituted or at least one R- 10a substituted dioxaborinanyl group; wherein R 10a is as defined in claim 5.

7. The compound according to claim 5, wherein R1 and R2 are each independently a sulfo group; a C1-C 10 alkoxy group; a glutamine group; a C2-C optionally substituted by C1-C6 alkyl 12 heterocyclylcarbonyloxy group; a C7-C optionally substituted by a C2-C optionally substituted by C1-C6 alkyl 12 heterocyclic group-substituted arylalkoxy group; a C2-C 21 carbonate alkoxy group; or 10 R1 and R2 are bonded to each other to form an optionally oxo-, formyloxy-, acetyloxy-, C1-C6 alkyl-, C1-C6 alkoxy-, optionally C6-C substituted by C1-C6 alkoxy aryl group, an optionally C7-C substituted by C1-C6 alkoxy 12 arylalkyl group, or a C2-C optionally substituted by hydroxy, formyloxy, acetyloxy, C1-C6 alkyl or C1-C6 alkoxy 13 heterocyclic group-substituted dioxolanyl group, dioxanyl group or dioxaborolanyl group; 12 Preferably, R1 and R2 are each independently: or R1 and R2 are bonded to each other to form: wherein, * and *' each represent a binding site to an adjacent atom on the benzene ring.

8. The compound according to any one of claims 5 to 7, wherein the compound represented by Formula 1 is selected from the following Compounds 2 to Compound 18:

9. A pharmaceutical composition comprising the compound according to any one of claims 5 to 8, and a pharmaceutically acceptable excipient.

10. Use of the pharmaceutical composition according to claim 9 in the preparation of a medicament for treating a disease associated with reperfusion injury.​